HOLX vs STRO · P/E 32, rev $4.10B vs rev $62.0M
Hologic Inc (HOLX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Hologic Inc (HOLX) is a medical instruments & supplies company listed on NASDAQ.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported HOLX revenue for 2025-09-27 was $4.10B. Net income was $565.7M. Revenue was up 1.7% from 2024-09-28 to 2025-09-27. HOLX currently screens at market cap $16.97B and trailing P/E 31.5.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
HOLX currently screens at market cap $16.97B and trailing P/E 31.5. STRO currently screens at market cap $470.8M.
Not investment advice. Open the HOLX and STRO stock pages for the full models.
Not investment advice.